Table 4.

Survival Probabilities With Adjusted Hazard Ratios in Those Who Had Potential Poor-Quality Metrics^a

Variable	5-Year OS	Unadjusted HRb	Adjusted HRb
Positive margin (n = 152,903)	0.32 (0.31-0.33) vs 0.59 (0.59-0.60)	2.38 (2.31-2.46)	2.03 (1.96-2.09)
Wedge resection (n = 152,903)	0.53 (0.52-0.53) vs 0.59 (0.58-0.59)	1.17 (1.14-1.20)	1.20 (1.17-1.23)
pNX (n = 122,514)	0.50 (0.49-0.52) vs 0.64 (0.64-0.64), pN0	1.54 (1.48-1.60)	1.48 (1.43-1.54)
< 10-lymph node resection among pathologic stage I-IIc (n = 120,693)	0.61 (0.60-0.61) vs 0.63 (0.62-0.63)	1.06 (1.04-1.09)	1.07 (1.05-1.09)
Non-evidence-based use of adjuvant radiation therapyd (n = 129,412)	0.41 (0.39-0.42) vs 0.62 (0.62-0.63)	1.97 (1.88-2.06)	1.70 (1.62-1.78)
Non-evidence-based use of adjuvant chemotherapye (n = 101,561)	0.64 (0.63-0.66) vs 0.66 (0.65-0.66)	1.05 (1.01-1.09)f	1.11 (1.07-1.16)

Data are presented as OS (95% CI) or HR (95% CI). HR = hazard ratio; OS = overall survival; pN0 = pathologic node-negative; pNX = resection without lymph node examination.

^aHazard ratios adjusted for age at diagnosis, race or ethnicity, sex, year of diagnosis, insurance, geographic region of the facility, comorbidity score, and clinical stage.

^bP < .0001 unless otherwise stated.

^cAmong patients with pathologic stage I-II, including patients with 0 lymph nodes, excluding patients with unknown number of nodes.

^dPatients with pathologic N0 and N1 and negative resection margins.

^ePatients with pathological stage I with tumor size ≤ 4 cm and negative resection margins.

^fP = .0238.